1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.

Slides:

Advertisements

Similar presentations

Medicare and Prescription Drugs: Issues for Employers and Consumers Robert D. Reischauer The Urban Institute National Health Policy Conference January.

Advertisements

Medicaid Update 2013 John J. Wernert, MD President, Professional Development Associates, LLC Medical Director, Medical Management Wishard Health System.

Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.

The Medicare Drug Discount Card: A public-private partnership July 28, 2004 Grace-Marie Turner Galen Institute.

Opportunities to Leverage HIT for Medicaid Reform in New York Rachel Block, United Hospital Fund C. William Schroth, NYS Department of Health eHealth Initiative.

The Implications of the New Medicare Prescription Drug Legislation for Health Care Providers Anthony A. Barrueta Senior Counsel, Government Relations Kaiser.

Medicare & Medicaid. 2 Medicare – Medical Care for the Elderly l Institutional features – Part A—Hospital insurance – Part B—Physician, Outpatient hospital,

Supplementing PACE through Medicare Part D

Expanding Health Insurance Coverage James R. Tallon, Jr. President, United Hospital Fund Bipartisan Congressional Health Policy Conference January 13,

The A – B – C (and D) of Medicare September 12, 2011 Grace-Marie Turner Galen Institute.

THE AIDS INSTITUTE The AIDS Institute HEALTH REFORM AND ADAP Emily McCloskey, Public Policy Associate Carl Schmid, Deputy Executive Director AIDS Drug.

MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.

MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.

Overview of the U.S. Health Care System OU Pre-med Club/AMSA September 27, 2006.

Deciphering Medicare Part D Susan Miller, Patient Education Douglas A. Magenheim, MD, MBA, FACP.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.

Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.

Strategic Implications of the New Medicare Prescription Drug Legislation G. Lawrence Atkins, PhD Schering-Plough Corporation The Pharma, Biotech and Device.

MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.

1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.

Copay Structure Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?

Medicare Prescription Drug Benefit: Part D Health & Disability Advocates Stephanie Altman, J.D Ext

MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.

Medicare Update Presented by Tricia Neuman, Sc.D. Vice President, Henry J. Kaiser Family Foundation for Grantmakers in Health November 4, 2004.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.

Exhibit 1. “Medicare Extra” Benefits vs. Current Medicare Benefits Current Medicare benefits*“Medicare Extra” Deductible Hospital: $1024/benefit period.

State Strategies: Expanding Prescription Drug Access Dee Mahan Families USA November 1, 2002.

Michigan Medicaid Pharmacy Cost Containment Paul Reinhart, Director Medical Services Administration Michigan Department of Community Health October 8,

Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.

 The Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues Presented By: Jack Rodgers PricewaterhouseCoopers February 27,

Comparison of Health Care Reform Bills 2010 Contemporary Problems in Economics Professor Steve Cunningham 1.

Impact of the MMA on Dual Eligible Beneficiaries and State Medicaid Programs Joy Johnson Wilson, Health Policy Director, NCSL June 28, 2005.

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Robin Rudowitz Associate Director Kaiser Commission on Medicaid and the Uninsured.

MEDICARE PART D.

State Opportunities under the 340B Drug Discount Program by Bill von Oehsen Counsel Public Hospital Pharmacy Coalition Phone:

Medicare Part D Symposium Thursday, September 1, 2005 Sacramento, CA Cathy Senderling Senior Legislative Advocate, CWDA.

The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.

THE COMMONWEALTH FUND Medicare Part D: What Are The Concerns? Stuart Guterman Director, Program on Medicare’s Future The Commonwealth Fund Association.

Return to Tutorials Tricia Neuman, Sc.D. Director, Medicare Policy Project Vice President, Kaiser Family Foundation For KaiserEDU June 2009 Medicare 101:

Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.

Slide 1 Drug Pricing Considerations Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ___________ Copyright 2005 Arnold & Porter July.

Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.

THE COMMONWEALTH FUND Figure 1. Medicare’s Success in Achieving Major Goals “How successful has Medicare been in accomplishing each of the following specific.

IMPACT OF SECTION 18 for CITY OF SPRINGFIELD AND CITY RETIREES January 31, 2005.

Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Medicare Modernization Act of 2003: Implications for Low-Income People and State.

 Putting Numbers on the New Medicare Prescription Drug Legislation: How the MMI Will Affect Medicare Beneficiaries and Pharmaceutical Revenues Jack.

"Helping Seniors Make Smart Decisions about their Drug Coverage Options" Hal Prink, FHFMA, Medicare Patient Advocate, Senior’s Voice for Healthcare Rights.

Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.

MEDICARE’S 2006 TAKEOVER OF PRESCRIPTION DRUG COVERAGE FOR DUAL ELIGIBLES IN NURSING FACILTIES: ISSUES AND CONCERNS Jim Verdier Mathematica Policy Research,

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

The Basic Health Program: Findings from Maryland’s Report Chuck Milligan Deputy Secretary, Health Care Financing DHMH February 14,

Third National Medicare Congress Marta Schroeder Divisional Vice President Public Health Policy & Strategy October 2006.

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.

Estimating the Cost of the Medicare Drug Benefit Philip Ellis Steve Lieberman Medicare Prescription Drug Congress February 27, 2004.

1 Medicare Prescription Drug Legislation: A Perspective from the Battlefield Tom Scully National Medicare Prescription Drug Congress February 25, 2004.

MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.

The Arkansas Health Care Independence Program An Alternative to Medicaid Expansion Richard Armstrong Director Department of Health and Welfare December.

Avalere Health LLC | The intersection of business strategy and public policy Enrollment in the Medicare Drug Benefit Medicare Congress Audioconference.

Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.

Health Policy VIVIAN HO, PH.D. BAKER INSTITUTE CHAIR IN HEALTH ECONOMICS DIRECTOR, CENTER FOR HEALTH AND BIOSCIENCES PROFESSOR, DEPARTMENT OF ECONOMICS,

Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.

MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.

The Third National Medicare Congress David B. Snow, Jr.

Medicare Rx Legislation: Implications for PBMs

Medicare Rx Drug Benefit

Presented by Tricia Neuman, Sc.D.

Setting the Stage for Federal Action on Medicaid Reform June 6, 2006

Medicare Reform: Implications for Pharmaceutical Manufacturers

Presentation transcript:

1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004

2 Major Changes Affecting Pharmaceuticals Medicare-Approved Drug Discount Cards Medicare Prescription Drug Benefit Medicare Advantage (MA) and Prescription Drug Plans (PDPs). Transfer of “Dual-Eligibles” to Medicare Drug Benefit Federal Low-Income Subsidies Payment Changes for Existing Medicare-Covered Drugs Electronic Prescribing Canada Importation Hatch-Waxman Reforms

3 Medicare Discount Cards Medicare “approval” – builds on existing care programs. Manufacturer-sponsored cards not included. Together RX? $600 annual subsidy will expand drug spending in the short term (2004 and 2005). Estimated 4.7 million of the 7.3 million beneficiaries using the card will get a subsidy. Use of formularies and limit of enrollees to one card at a time are expected to increase card-sponsor leverage for manufacturer discounts. Posting of retail prices may increase competitive pressures. Card and subsidy will affect participation in manufacturers’ patient assistance programs.

4 Medicare Drug Benefit: Impact Implementation delayed to % of Medicare beneficiaries (seniors and disabled) currently without coverage will get coverage. Federal resources will be provided to entities already providing drug coverage : Medicaid -- dual eligibles shift to Medicare plans (with clawback) Employers -- retiree health plans receive 28% of benefit subsidy Medicare+Choice plans Substantial federal assistance to low-income beneficiaries – will double the size of the population with little or no out-of-pocket costs.

5 Value of the Medicare Drug Benefit Annual Drug Expenses Medicare Pays Beneficiary Pays Premium (Annual) Pct of Cov’d Expenses $1,000$562$438$42056% $2,500$1,500$1,000$42060% $5,000$1,500$3,500$42030% $10,000$6,155$3,845$42062%

6 Impact of Drug Benefit Muted Increase in drug utilization will be limited: –Medicare benefit will pick up only 30 to 60 percent of drug expenses. –Beneficiaries will have high cost sharing. –Much of the federal spending will subsidize existing coverage, not expand coverage. Major impact on utilization will come from expansion of Federal low- income assistance. Drugs will be sold in a more competitive environment. Use of private drug plans increase share of the market subject to private purchasing methods. Transfer of Medicaid “dual eligibles” to private Medicare plans will reduce the impact of state supplemental rebates and PDLs.

7 “Dual Eligibles” Will transfer 60% of state Medicaid pharmacy cost to the federal government. Will shift former Medicaid beneficiaries to private drug plans; with full low-income assistance. Will significantly reduce size of rebates. Will also reduce ability of states to negotiate supplemental rebates. State rebate loss and federal “clawback” will deprive states of savings from the transfer. –CBO estimates 10-year net savings to states of $17.2 billion. –States will have added administrative cost.

8 Low-Income Assistance Major expansion in assistance to low-income individuals. Doubles the number of eligible Medicare beneficiaries: –All 6.4 million “dual eligibles” will receive full federal subsidies (leaving only small copayments). –Another 5.8 million beneficiaries will be eligible for full federal subsidies. –1.9 million more will be eligible for partial subsidies. Reduces the need for state pharmaceutical assistance programs. Reduces demand for manufacturer-sponsored patient assistance (“free drug”) programs.

9 Private Plans Pharma supported reliance on private competing prescription drug plans (PDPs and Medicare Advantage). Private approach strengthens purchaser leverage – PBMs, MCOs. Negotiated prices will be exempt from Medicaid “best price,” encouraging deeper discounts. Question of capacity of PBMs to handle enrollment and bear drug risk. –Failure would lead to Fallback and HHS assumption of risk. Electronic prescribing standards (2008) –Will require that prescribers receive information on alternative low-cost drugs.

10 Other Issues Cost Containment –Danger of triggering near-term financing crisis and price controls. Medicare payment to providers for Part B and HOPPS drugs –Brings reimbursement closer to cost. Hatch-Waxman Changes –Eases market entry for generics. Canada Importation –Potential authority to import from Canada, pending certification by the HHS Secretary.

11 Positives for Drug Manufacturers Expanded drug benefit coverage. Doubling of low-income assistance. Private-sector management of drug benefits. Transfer of Medicaid seniors to private plans – reduction in rebates. Expansion of integrated health plan enrollment.

12 Negatives for Drug Manufacturers Substantial cost sharing for seniors with the benefit. Increase in purchasing clout by PBMs and private health plans. Potential for Fallback and government involvement. Shift of price pressure from seniors to government. Potential for cost containment measures and price controls. Potential for Canada importation.